With over twenty years of experience in the pharmaceutical and biotech industries, May has successfully led all aspects of clinical development from Phase 1 to market. She has experience in a broad range of therapeutic areas including Rare and Orphan disorders and Gene Therapy, which are both highly relevant to PYC’s efforts. As a CMO and as an advisor, May has helped small biotech companies like PYC develop rare disease programs by collaborating with discovery, clinical, and commercial teams. May also brings big pharma experience, having spent nearly a decade at Pfizer, where she held various leadership roles and was instrumental in building its rare disease unit.
May completed her Fellowship in Paediatric Oncology/Haematology at Massachusetts General Hospital and Children’s Hospital, Boston, MA, after practicing as a specialised CNS Oncology Clinical Research physician at Dana-Farber Cancer Institute in Boston, MA. May holds a medical degree from the University of Baghdad, Baghdad, Iraq, and a Pharmaceutical Masters of Business Administration from Cambridge University, Cambridge, England.